Investor Relations

Company Profile

Profound Medical Corp. has commercialized ground-breaking technology in the area of localized prostate cancer.

With our minimally invasive procedure called MRI-Guided TULSA (Transurethral Ultrasound Ablation), we are able to ablate cancerous prostate tissue, from the inside out, in a single session. A continuous volume of thermal ablation (to 57 °C) is delivered in less than 40 minutes, depending upon the size of the prostate. The patient goes home within 24 hours of the procedure. Faster patient recovery and significantly reduced side effects (bowel complications, incontinence, erectile dysfunction), enables patients and their partners to quickly resume their quality of life.

Profound Medical is committed to make a significant difference in the future of men’s health.

Investor FAQ

What is Profound Medical’s Business?
Profound Medical, based in Mississauga, Ontario, is a medical device company that has developed ground-breaking technology in the area of localized prostate cancer.

When was Profound Medical founded?
Profound Medical was founded in 2008.

What is Profound Medical’s Product?
MRI-Guided TULSA (Transurethral Ultrasound Ablation) is a real-time, MRI guided, transurethral ultrasound procedure that ablates cancerous and non-cancerous prostate tissue from the inside out. TULSA-PRO™ is the device that is comprised of several components (capital equipment and single-use disposables).

After successful completion of the Phase I Clinical Trial, the technology continues to be assessed for efficacy in large prostate cancer patient populations.

What is Profound Medical’s Regulatory Status?
TULSA-PRO™ has CE Marking. Regulatory Authorization is pending for all other jurisdictions.

Where can I find the current share price?
The current share price can be found by searching for the ticker symbol “PRN” at; http://web.tmxmoney.com/quote.php?qm_symbol=PRN

Where can I access Profound Medical’s financial statements?
Please visit SEDAR

Newsroom 2017

Profound Medical Corp. to Release First Quarter 2017 Financial Results on May 9, 2017 – Conference Call to Follow
April 25, 2017, Press Release

Profound Medical Corp. Obtains DTC Eligibility for its Common Shares in the U.S.
April 18, 2017, Press Release

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth
March 28, 2017, BioTuesdays

Profound Medical Corp. Announces First Paid Procedure Using TULSA-PRO® System
March 27, 2017, Press Release

Profound Medical Corp. Announces Management Change
March 24, 2017, Press Release

Profound Medical Corp. and Philips Announce first TULSA-PRO® Sale in Finland to Turku University Hospital
March 20, 2017, Press Release

OTC Market Groups Welcomes Profound Medical to OTCQX
March 13, 2017, OTC Press Release

Profound Medical Corp. to Begin Trading on OTCQX on March 13, 2017
March 9, 2017, Press Release

Profound Medical Corp. Announces Fourth Quarter and Full Year 2016 Financial Results
March 6, 2017, Press Release

Profound Medical Corp. to Release Fourth Quarter and Full Year 2016 Financial Results on March 6, 2017 – Conference Call to Follow
February 21, 2017, Press Release

Profound Medical to Participate in 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference
February 14, 2017, Press Release

Profound Medical Announces Special Meeting of Shareholders Voting Results
January 26, 2017, Press Release

Kenneth Galbraith joins Profound Medical Board
January 18, 2017, BioTuesdays

Profound Medical Announces Appointment of Kenneth Galbraith to its Board of Directors
January 17, 2017, Press Release

Newsroom 2016

Profound Medical Corp.  Announces Third Quarter 2016 Financial Results
November 16, 2016, Press Release

Profound Medical Corp. Completes Previously Announced $17.4 Million Bought Deal Offering of Common Shares
November 14, 2016, Press Release

Profound Medical Corp. to Present at the 2016 Canaccord Genuity Medical Technologies & Diagnostics Forum
November 3, 2016, Press Release

Profound Medical Corp. to Present at the Stifel 2016 Healthcare Conference
November 1, 2016, Press Release

Profound Medical Corp. to Release Third Quarter 2016 Financial Results on November 16, 2016 – Conference Call to Follow
October 26, 2016, Press Release

Profound Medical Corp. Announces $17.4 Million Bought Deal Financing
October 17, 2016, Press Release

Profound Medical Receives Frost & Sullivan’s 2016 New Product Innovation Award
October 5, 2016, Press Release

Profound Medical Corp. Announces First Patient Treated in TACT Pivotal Clinical Trial at Vanderbilt University Medical Center
September 22, 2016, Press Release

New to the Neighbourhood: Profound Medical comes to Mississauga
September 1, 2016, Biotechnology Focus

Profound Medical Corp. Announces Second Quarter 2016 Financial Results
August 18, 2016, Press Release

Profound Medical names Arun Menawat as CEO
August 16, 2016, BioTuesdays

Profound Medical Corp. Announces Senior Management Changes to Support Global Growth Strategy
August 15, 2016, Press Release

Mackie starts Profound Medical at speculative buy
August 10, 2016, BioTuesdays

Profound Medical Corp., to Release Second Quarter 2016 Financial Results on August 18, 2016
August 10, 2016, Press Release

Profound Medical Corp., Announces Annual Meeting of Shareholders Voting Results
June 22, 2016, Press Release

Profound Medical Corp., and Philips sell TULSA-PROTM System to University Hospital of Cologne, Germany
June 21, 2016, Press Release

Profound Medical Corp., and Philips sell TULSA-PROTM System to UCL and UCLH
June 20, 2016, Press Release

Revolutionizing Prostate Cancer Treatment, investinontario.com
June  2016, investinontario.com

Profound Medical Corp. to hold Annual General Meeting of the Shareholders
June 7, 2016, Press Release

FDA Grants Profound Medical Corp. IDE Approval for TULSA-PROTM
May 19, 2016, Press Release

Profound Medical Corp  and Philips Sign Sales and Marketing Agreement in MRI -guided therapy in Prostate Cancer Care
May 11, 2016, Press Release

Profound Medical Corp  Announces First Quarter 2016 Financial Results
May 6, 2016, Press Release

Profound Medical Corp. to Present at Upcoming Conference 
April 29, 2016, Press Release

Profound Medical  Corp. to Release First Quarter 2016 Financial Results on May 6, 2016 
April 29, 2016, Press Release

Profound Medical Corp. Announces World’s First Sale of TULSA-PRO for Prostate Ablation
April 28, 2016, Press Release

Profound Earns European Approval for Prostate Device
April 22, 2016, Focused Ultrasound Foundation

GMP starts Profound Medical at speculative buy
April 13, 2016, BioTuesdays

Profound Medical Corp.  Receives CE Mark Approval for TULSA-PRO
April 11, 2016, , Press Release

Profound Medical Corp.  Announces Full Year 2015 Financial Results
March 2, 2016, Press Release

Profound Medical Corp. and Siemens Enter into Strategic Agreement to Further the Development of Prostate Cancer Care
February 29, 2016, Press Release

Profound Medical Corp. to Release Full Year 2015 Financial Results on March 3, 2016
February 25, 2016, Press Release

Profound Medical Corp., Announces Publication in European Urology
January 8, 2016, Press Release

Newsroom 2015

Profound Medical named 2016 Life Science Company of the Year
November 27, 2015, Press Release

A Brighter Future: Advancements in Prostate Cancer Therapy Minimize Side Effects for Patients
November 20, 2015, Media Planet Supplement, Toronto Star

Profound Medical Corp. Announces Departure of CFO
November17, 2015, Press Release

Profound Medical Corp. Announces Third Quarter 2015 Financial Results
November 5, 2015, Press Release

Hartmut Warnken joins Profound Medical as Vice President, International Sales
November 2, 2015, Press Release

Profound Medical Corp. to Release Third Quarter 2015 Financial Results on November 4, 2015
October 28, 2015, Press Release

Profound Medical to Present at Upcoming Investor Conferences
October 21, 2015, Press Release

Profound Medical Presents Successful 12-Month Phase 1 Outcomes at the European Symposium on Focused Ultrasound Therapy
October 15, 2015, Press Release

Profound Medical to present 12-month outcomes of Phase 1 Clinical Trial at European Symposium on Focused Ultrasound Therapy
October 13, 2015, Press Release

Profound Medical Announces Grant of Share Options
September 18, 2015, Press Release

Profound Medical Corp. Announces Second Quarter 2015 Financial Results
August 25, 2015, Press Release

Profound Medical Corp. Announces First Quarter 2015 Financial Results of Profound Medical Inc.
July 29, 2015, Press Release

Philips and Profound Medical Collaborate to Advance Treatment for Prostate Cancer Patients
July 21, 2015, Press Release

Profound Medical Corp. Announces Annual Meeting of Shareholders Voting Results
June 23, 2015, Press Release

Profound Medical Opens the Market
June 15, 2015, Press Release

Profound Medical Goes Public via Reverse Takeover
June 1, 2015, Biotechnology Focus

Profound Medical Corp. Announces Closing of Qualifying Transaction
June 4, 2015, Press Release

Profound Medical seeking CE Mark for TULSA-PRO This Year
May 26, 2015, Bio Tuesdays

Profound Medical and Shopify show Contrasting Ways to go Public
May 25, 2015, Financial Post

Mira IV Acquisition Corp. Announces Filing of Filing Statement
May 25, 2015, News Release

Preclinical safety and feasibility with 28-day follow-up
May 2015, Journal of Urology, Vol. 192

PMI Announces Going-Public Transaction and Concurrent $28 Million Financing to Fund Next Stage of Growth
April 30, 2015, News Release

Mira IV Acquisition Corp. Announces entering into of an Amalgamation Agreement with PMI
April 29, 2015, News Release

investor-relations

Clinical Publications

2017: Transurethral MR-Thermometry Guided Ultrasound Ablation of the Prostate – The Heidelberg Experience During Phase I of the TULSA-PRO Device Trial, Mueller-Wolf et al

2016: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial, Chin et al

2015: Magnetic Resonance Image Guided Transurethral Ultrasound Prostate Ablation: A Preclinical Safety and Feasibility Study with 28-Day Follow-up, Burtnyk et al

2014: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Prospective Trial Phase l Clinical, Midterm Results, Chin et al

2012: MR Imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: Initial feasibility in humans, Chopra et al

2012: Investigation of power and frequency for 3D conformal MRI-controlled transurethral ultrasound therapy with a dual frequency multi-element transducer, N’Djin et al

2012: Coagulation of human prostate volumes with MRI-controlled transurethral ultrasound therapy: results in gel phantoms, N’Djin et al

2010: MRI-controlled transurethral ultrasound therapy for localized prostate cancerChopra et al

2010: Simulation study on the heating of the surrounding anatomy during transurethral ultrasound prostate therapy: A 3D theoretical analysis of patient safety, Burtnyk et al

2010: 3D Conformal MRI-controlled transurethral ultrasound prostate therapy: validation of numerical simulations and demonstration in tissue-mimicking gel phantoms, Burtnyk et al

2010: MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies, Siddiqui et al

2009: Quantitative analysis of 3D conformal MRI-guided transurethral ultrasound therapy of the prostate: theoretical simulations, Burtnyk et al

2009: Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback, Chopra et al

2008: MRI-compatible transurethral ultrasound system for the treatment of localized prostate cancer using rotational control, Chopra et al

2007: Prostate tissue analysis immediately following magnetic resonance imaging guided transurethral ultrasound thermal therapy, Boyes et al

2007: Conformal thermal therapy using planar ultrasound transducers and adaptive closed-loop MR temperature control: demonstration in gel phantoms and ex vivo tissues, Tang K et al

2006: Analysis of factors important for transurethral ultrasound prostate heating using MR temperature feedback, Chopra et al

2005: Method for MRI-guided conformal thermal therapy of prostate with planar transurethral ultrasound heating applicators, Chopra et al

Investor Presentations

Financial Statements

Investor Relations Contact

seperator-profound-sm

Stephen Kilmer, Investor Relations
skilmer@profoundmedical.com
647.872.4849

Subscribe

To receive financial information via email, please complete this form;

Toggle 1

Toggle 2